CD Biosynsis offers integrated Sf9 Cells Metabolic Pathway Optimization Services, utilizing advanced genetic and computational strategies to enhance the efficiency and product quality of recombinant protein production via the Baculovirus Expression Vector System (BEVS). Sf9 cells (derived from Spodoptera frugiperda) are key hosts for producing complex proteins requiring eukaryotic folding, but optimization is essential for industrial scale. Our services employ a systematic approach combining Metabolic Modeling (CBM), high-precision genome editing (CRISPR-Cas9, Base Editing, CRISPRi), and High-Throughput Screening (HTS). This integrated strategy allows for the rational identification and removal of metabolic bottlenecks, optimization of nutrient utilization, and enhancement of the protein processing capacity (e.g., disulfide bond formation). Our goal is to develop highly optimized Sf9 cell lines that exhibit superior viability, productivity, and tailored glycosylation profiles for biotherapeutic and vaccine applications.
Get a QuoteOptimizing the Insect Cell/BEVS system requires managing the high metabolic load imposed by both the viral infection and high-level protein production. Our platform employs a systematic cycle where metabolic modeling (Design) guides the construction of engineered strains (Build). Phenotypic testing (Test) and data analysis (Learn) inform the next round of rational modifications. Key goals include minimizing the production of toxic byproducts, enhancing nucleotide sugar availability for glycosylation, and extending the viability of the culture post-infection. This approach dramatically increases the final yield and structural integrity of complex recombinant proteins.
Constraint-Based Metabolic Modeling (CBM)
Utilization of the insect cell genome-scale model to predict nutrient requirements, optimize substrate uptake, and identify metabolic limitations during the highly demanding post-infection phase.
Metabolomics & Fluxomics
Experimental measurement of central carbon and nucleotide sugar fluxes (via ${}^{13}\text{C}$ tracing) to pinpoint bottlenecks in energy supply and glycosylation capacity.
Proteomics & Secretomics
Quantitative analysis of host protein expression to monitor chaperone availability (e.g., BiP) and secretion pathway capacity in response to viral and expression stress.
CRISPR-Cas9 Editing
Used for stable multi-gene knock-in of mammalian pathways (Glycoengineering) and multi-locus knockout of native proteases and undesirable PTM enzymes.
Base Editing (BE)
Precision single-nucleotide substitutions for fine-tuning native host gene expression (promoters/UTRs) or subtly modifying enzyme activity in folding or metabolic pathways.
CRISPR Interference (CRISPRi)
Tunable and reversible gene repression (knockdown) for safely balancing flux through essential energy pathways or managing the host's response to viral infection.
Humanized Glycoengineering
Full pathway modification (KO/KI) to eliminate immunogenic insect glycans (e.g., $\alpha(1,3)$-fucose) and introduce human-compatible N-glycosylation structures.
Enhanced Folding & Secretion
Overexpression or tuning of ER-resident chaperones and folding catalysts (e.g., PDI) to improve the yield and solubility of complex, disulfide-bonded proteins.
Extended Viability Post-Infection
Engineering host cell survival pathways or metabolism to extend the window of high productivity after baculovirus infection, boosting final titer.
A systematic and iterative process for developing high-performance production cell lines.
1. Modeling & Target Identification
2. Precision Editing & Strain Construction
3. High-Throughput Phenotype Screening
4. Data Integration & Strain Delivery
Utilize the insect cell CBM to simulate viral load/expression stress and identify metabolic bottlenecks (e.g., glucose/glutamine shunts, nucleotide sugar limits).
Design a set of rational genomic modifications (KO of native PTMs, KI of human PTMs, tuning of energy enzymes) guided by model predictions.
Define screening assays (e.g., titer, glycan profile, viability post-infection) based on optimization goals.
Execute multiplex genome editing (CRISPR-Cas9, Base Editing, CRISPRi) for stable integration or deletion in the insect host line (Sf9/Hi5).
Select for edited clones using antibiotic selection or reporter-based sorting.
Generate monoclonal cell lines for immediate testing.
Integrate screening and assay data back into the metabolic model to validate predictions and refine design rules.
Select the final optimized clone based on titer, stability, folding capacity, and product quality metrics.
Delivery of the verified insect cell master cell bank (MCB) and comprehensive optimization report.
Integrated Glycan Optimization
Combines metabolic modeling (nucleotide sugar availability) and genome editing (KO/KI) to ensure stable, high-level production of human-compatible N-glycans, a critical BEVS enhancement.
Folding & Secretion Enhancement
Targeted tuning of ER folding capacity and PDI expression maximizes the yield and solubility of complex proteins (e.g., viral proteins, therapeutic antigens).
Post-Infection Viability
Strategies enhance cell survival and metabolic robustness during the high-stress, high-production post-infection phase, directly extending the yield window.
Stable Genomic Integration
Engineering modifications are integrated into the host chromosome via CRISPR/HDR, providing consistent, reliable, and virus-independent strain performance.
1. What is the biggest metabolic challenge in the Insect Cell/BEVS system?
The biggest challenge is managing the acute metabolic stress and cell death (lysis) triggered by the baculovirus infection, which severely limits the time window for high productivity.
2. How does CBM help optimize insect cell production?
CBM identifies metabolic bottlenecks related to high energy demand and nucleotide sugar synthesis during high-level expression, guiding the engineering of pathways to provide enhanced cofactors and building blocks.
3. Can you extend the high-productivity phase post-infection?
Yes. We use genome editing to target host cell apoptosis pathways or tune stress response genes, enhancing cell survival during the late stages of the lytic viral cycle, thereby extending the production window.
4. How is the undesirable $\alpha(1,3)$-fucose eliminated?
It is eliminated by permanent knockout (CRISPR-Cas9) of the native host enzyme responsible for adding this immunogenic sugar (e.g., a specific fucosyltransferase), followed by verification using glycan analysis.
5. What is the role of Base Editing in insect cell optimization?
Base Editing is used for fine-tuning the expression of native host factors (e.g., chaperones) or metabolic enzymes, providing precise modulation of activity that is essential for balanced pathway flux.
6. How do you ensure the stability of pathway modifications?
All permanent modifications (KO/KI) are integrated into the host chromosome via CRISPR/HDR, ensuring the modified traits are genetically stable and passed on reliably to all progeny, independent of the viral vector.
7. What is included in the final delivery?
We deliver the verified, optimized insect cell Master Cell Bank (MCB), the final metabolic model, and a detailed report covering the editing strategy, genomic verification, and fed-batch performance data (titer, viability, and CQA analysis).
8. Which insect cell lines do you support for this service?
We primarily support Spodoptera frugiperda lines (Sf9, Sf21) and Trichoplusia ni lines (High Five, Hi5), applying optimization strategies tailored to the specific characteristics and limitations of the chosen host.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.